Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer
Mr. Claiborne brings extensive experience in leadership roles with clinical and commercial stage, publicly traded biopharmaceutical companies.
Adial Pharmaceuticals
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder
Company plans to submit ONWARD results to both European and U.S. regulatory agencies.
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders
The research collaboration agreement will further evaluate the Company’s proprietary adenosine analogs as a potential treatment for inflammatory diseases.
Adial Pharmaceuticals Announces Closing of $10 Million Financing
The net proceeds of the offering strengthen Adial’s balance sheet as it moves toward completion of the Company’s Phase 3 ONWARD™ trial.
Adial Pharmaceuticals Receives Notice of Allowance on the U.S. Patent for the Treatment for Opioid Use Disorder Using AD04
Patent covers patients with a specific genetic biomarker for the serotonin-3 receptor.